Autres langues IRLAB Therapeutics AB

Actions

IRLAB A

SE0012675361

Produits pharmaceutiques

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 07/07/2026			Varia. 5j.	Varia. 1 janv.
1,394 ^SEK	+6,41%		+12,42%	-29,24%

30/06	IRLAB Therapeutics AB (publ) approuve l'élection de Janne Backman au poste de vice-président du conseil d'administration	CI
30/06	L'augmentation de capital d'IRLAB Therapeutics lève environ 68 millions de couronnes suédoises	RE

Autres langues

30/06	IRLAB Therapeutics AB Approves Election of Janne Backman as Vice Chairperson of the Board of Directors
30/06	Report from the Annual General Meeting 2026 of IRLAB Therapeutics AB
30/06	IRLAB Therapeutics Rights Issue Raises About SEK 68 Mln
30/06	Irlab Therapeutics Raises SEK76.5 Million from Oversubscribed Rights Offering
16/06	IRLAB Therapeutics Presents Integrated Analysis of Mesdopetam Data at International Conference and Confirms Robust Efficacy Results in The Phase II Studies
16/06	IRLAB Presents Integrated Analysis of Mesdopetam Data at International Conference - Confirms Robust Efficacy Results in the Phase II Studies
16/06	IRLAB presents integrated analysis of mesdopetam data at international conference – confirms robust efficacy results in the Phase II studies
05/06	IRLAB Therapeutics AB Announces Board Elections, Effective June 5, 2026
05/06	IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received
05/06	Report from the Extraordinary General Meeting of IRLAB Therapeutics AB
03/06	IRLAB Participates at Aktiedagarna in Stockholm on June 9
03/06	IRLAB participates at Aktiedagarna in Stockholm on June 9.
06/05	IRLAB Therapeutics : Financial Report (irlab q1 2026 eng final)
06/05	IRLAB Q1 operating result swings to profit of SEK 10.7 mln
06/05	IRLAB Therapeutics : publishes interim report for the period January – March 2026
06/05	IRLAB publishes interim report for the period January - March 2026
06/05	IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2026
05/05	Irlab resolves on rights issue, obtains extended loan financing
05/05	IRLAB resolves on a rights issue of approximately SEK 68 million with an overallotment issue and obtains extended loan financing
30/04	IRLAB: Invitation to the interim report for Q1 2026 presentation and webcast
29/04	IRLAB publishes the Annual Report for 2025
17/04	Christer Nordstedt Declines Re-Election as Board Member of IRLAB Therapeutics AB
17/04	Nomination Committee's proposal to the Board of Directors for IRLAB Therapeutics' Annual General Meeting 2026
17/04	Nomination Committee’s proposal to the Board of Directors for IRLAB Therapeutics’ Annual General Meeting 2026
09/04	IRLAB to present at Redeye Healthcare Day 2026